Document:

Exhibit
4.1

THE TERMS AND CONDITIONS OF THE RIGHTS
OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS SUPPLEMENT DATED APRIL 21, 2021 (THE “PROSPECTUS SUPPLEMENT”)
AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS AND PROSPECTUS SUPPLEMENT ARE AVAILABLE UPON REQUEST FROM BROADRIDGE
CORPORATE ISSUER SOLUTIONS, INC., THE SUBSCRIPTION AGENT, BY CALLING (855) 793-5068.

SUMMIT THERAPEUTICS INC.

Incorporated under the laws of the State of Delaware

NON-TRANSFERABLE SUBSCRIPTION RIGHTS CERTIFICATE

Evidencing Non-Transferable Subscription
Rights to Purchase Shares of

Common Stock, Par Value $0.01 per share, of Summit Therapeutics Inc.

Subscription Price: To be determined as set forth below

THE SUBSCRIPTION RIGHTS WILL EXPIRE IF NOT EXERCISED ON OR BEFORE

5:00 P.M., EASTERN TIME, ON MAY 10, 2021 (THE “EXPIRATION DATE”)

REGISTERED OWNER:

THIS CERTIFIES THAT the registered owner
whose name is inscribed hereon is the owner of certain non-transferable subscription rights (each, a “Subscription Right”).
The Subscription Right entitles the holder thereof to subscribe for and purchase shares of common stock, par value $0.01 per share
(the “Common Stock”), of Summit Therapeutics Inc., a Delaware corporation (the “Company”), at a subscription
price per full share equal to the lesser of (i) $5.24 per share (the “Initial Price”) and (ii) the volume weighted-average
price of the Common Stock for the ten (10) consecutive trading days through and including the Expiration Date (the “Alternate
Price”), pursuant to a rights offering (the “Rights Offering”), on the terms and subject to the conditions set
forth in the Prospectus Supplement, which supplements the Company’s prospectus dated October 15, 2020 (the “Prospectus”).

    	1

     

    

Each stockholder will receive one Subscription
Right for each share of Common Stock owned as of 5:00 p.m., Eastern Time, on April 9, 2021 (the “Record Date”) and
each Subscription Right will entitle its holder to purchase 0.172598 shares of Common Stock at the Initial Price per full share.

The Subscription Rights represented
by this Non-Transferable Subscription Rights Certificate may be exercised by completing Form 1 and any other appropriate forms
on the reverse side hereof and by returning the full payment of the subscription price for each share of Common Stock in accordance
with the instructions contained herein.

This Non-Transferable Subscription Rights
Certificate is not valid unless countersigned by Broadridge Corporate Issuer Solutions, Inc., the Subscription Agent. Witness the
seal of Summit Therapeutics Inc. and the signatures of its duly authorized officers.

DATED: [•], 2021

	
   

	 	
   

	Chief Executive Officer	 	Chief Financial Officer

 

DELIVERY OPTIONS FOR NON-TRANSFERABLE
SUBSCRIPTION RIGHTS CERTIFICATE

Deliver other than in the manner or
to the addresses listed below will not constitute valid delivery.

 

	If delivering by hand or overnight courier:	 	If delivering by first class mail:
	 	 	 
	Broadridge Corporate Issuer Solutions, Inc.

Attn: BCIS IWS

51 Mercedes Way

Edgewood, NY 11717	 	Broadridge Corporate Issuer Solutions, Inc.

Attn: BCIS Re-Organization Dept.

P.O. Box 1317

Brentwood, NY 11717-0718

 

 

    	2

     

    

PLEASE PRINT ALL INFORMATION CLEARLY
AND LEGIBLY.

SECTION 1 –
EXERCISE OF SUBSCRIPTION RIGHTS

To subscribe for shares of Common Stock
pursuant to your Subscription Right, please complete lines (a) and (b) and sign in part (c). If you do not indicate the number
of Subscription Rights being exercised, or if you do not forward the full subscription payment for the number of Subscription Rights
that you indicate are being exercised, then you will be deemed to have exercised the maximum number of Subscription Rights that
may be exercised with the aggregate subscription payment you delivered to the Subscription Agent. Fractional shares of our Common
Stock resulting from the exercise of the Subscription Rights will be eliminated by rounding down to the nearest whole share, with
the total subscription payment being adjusted accordingly. Any excess subscription payments received by the Subscription Agent
will be returned, without interest, as soon as practicable.

(a)              
EXERCISE OF SUBSCRIPTION RIGHT:

		(i)	Basic Subscription Right

	I exercise	
   

	x	0.172598	=	
   

	x	$5.24	=	
        $

	 	(No. of shares

owned)	x	(Initial ratio)	=	(No. of Basic Subscription Shares Subscribed For)	x	(Initial Price)	 	(Amount Enclosed)

 

		(ii)	Over-Subscription Right: If you fully exercise your Basic Subscription Right, above, and wish to subscribe for additional
shares, you may exercise your Over-Subscription Right below.

	I exercise	
   

	x	 	$5.24	=	
        $

	 	(No. of Over-Subscription

Shares

Subscribed For)	x	 	(Initial

Price)	=	(Amount Enclosed)

 

(b)              
PAYMENT:

	 	Amount Enclosed	 
	Basic Subscription

Right:	
        $
	 ̈    Certified check drawn on a U.S. bank, or postal or express money order payable to Broadridge Corporate Issuer Solutions, Inc., as Subscription Agent.
	 	 	 
	Over-Subscription

Right:	
        $
	 ̈    Wire transfer directly to the escrow account maintained by Broadridge Corporate Issuer Solutions, Inc., as Subscription Agent.
	 	 	 
	Total Amount

Enclosed	
        $
	 

 

    	3

     

    

Method of Payment. All payments must
be made in U.S. dollars by wire transfer of funds, U.S. Postal money order or certified check drawn upon a U.S. bank payable to
 “Broadridge Corporate Issuer Solutions, Inc. (acting as Subscription Agent for Summit Therapeutics Inc.)”. The Subscription
Agent will not accept payment by any other means.

 

(c)               
SIGNATURE(S):

TO SUBSCRIBE: I acknowledge that I have
received the Prospectus Supplement for the Rights Offering and I hereby irrevocably subscribe for the number of shares indicated
above on the terms and conditions specified in the Prospectus Supplement. I hereby agree that if I fail to pay for the shares of
Common Stock for which I have subscribed, Summit Therapeutics Inc. may exercise its legal remedies against me.

This form must be signed by the registered
holder(s) exactly as their name(s) appear(s) on the certificate(s) or book entry or by person(s) authorized to sign on behalf of
the registered holder(s) by documents transmitted herewith.

	
   

	
   

	
   

	Signature(s) of Subscriber(s)	Date	Daytime Telephone Number(s)

 

If signature is by trustee(s), executor(s),
administrator(s), guardian(s), attorney(s)-in-fact, agent(s), officer(s) of a corporation or another acting in a fiduciary or representative
capacity, please provide the following information (please print). See the instructions.

	
    

	
   

	
   

	
   

	Name(s)	Full Title	Taxpayer ID # or Social Security #	Date

 

SECTION 2 –
SPECIAL ISSUANCE OR DELIVERY INSTRUCTIONS FOR SUBSCRIPTION RIGHTS HOLDERS

	(a) To be completed ONLY if the book-entry representing the Common Stock is to be issued in a name other than that of the registered holder. (See the Instructions.) DO NOT FORGET TO COMPLETE THE GUARANTEE OF SIGNATURE(S) SECTION BELOW.	 	
        (b) To be completed ONLY if the book-entry representing the Common
        Stock is to be issued to an address other than that shown on the front of this certificate. (See the Instructions.)

        DO NOT FORGET TO COMPLETE THE GUARANTEE OF SIGNATURE(S) SECTION
        BELOW.

 

	Print Full Name:	
 

	Print Full Name:	
 

	Print Full Address:	
 

	Print Full Address:	
 

	Taxpayer ID # or Social Security #:	
 

	Taxpayer ID # or Social Security #:	
 

 

    	4

     

    

SIGNATURE GUARANTEE

This must be completed if you have completed any portion of Section 2.

	Signature Guaranteed:	
 

	 	(Name of Bank or Form)
	 	 
	 	 
	By:	
 

	 	(Signature of Officer)
	 	 	 

 

IMPORTANT: The signature(s) should be
guaranteed by an eligible guarantor institution (bank, stock broker, savings & loan association or credit union) with membership
in an approved signature guarantee medallion program pursuant to Securities and Exchange Commission Rule 17Ad-15.

FOR INSTRUCTIONS ON THE USE OF NON-TRANSFERABLE
SUBSCRIPTION RIGHTS CERTIFICATES, CONSULT BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., THE SUBSCRIPTION AGENT, AT (855) 793-5068
(TOLL-FREE). THE RIGHTS OFFERING EXPIRES AT 5:00 P.M., EASTERN TIME, ON MAY 10, 2021, AND THIS NON-TRANSFERABLE SUBSCRIPTION RIGHTS
CERTIFICATE IS VOID THEREAFTER.

THE RIGHTS OFFERING HAS BEEN REGISTERED
OR QUALIFIED OR IS BELIEVED TO BE EXEMPT FROM REGISTRATION OR QUALIFICATION ONLY UNDER THE FEDERAL LAWS OF THE UNITED STATES AND
THE LAWS OF THE STATES IN THE UNITED STATES. RESIDENTS OF OTHER JURISDICTIONS MAY NOT PURCHASE THE SECURITIES OFFERED HEREBY UNLESS
THEY CERTIFY THAT THEIR PURCHASES OF SUCH SECURITIES ARE EFFECTED IN ACCORDANCE WITH THE APPLICABLE LAWS OF SUCH JURISDICTIONS.

    	5NOTE PURCHASE AGREEMENT

 

This NOTE PURCHASE AGREEMENT (this “Agreement”)
is made and entered into as of April 20, 2021 by and among Summit Therapeutics Inc., a Delaware corporation, with its principal place
of business at One Broadway, 14th Floor, Cambridge, MA 02142 (the “Company”), and the investor named on
Exhibit A hereto (the “Investor”).

 

Recitals

 

A.               
The Company and the Investor are executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by the provisions of Regulation D, as promulgated by the U.S. Securities and Exchange Commission (the “SEC”)
under the Securities Act of 1933, as amended;

 

B.                
The Investor wishes to purchase from the Company, and the Company wishes to sell and issue to the Investor a Promissory Note, in
the form attached hereto as Exhibit B, in the original principal amount of $55,000,000 (the “Note”), which shall
mature and come due upon the earlier of (i) the consummation of a public offering of securities registered under the Securities Act of
1933, as amended, by the Company with net proceeds of no less than $55,000,000 or (ii) thirteen (13) months from the date hereof, upon
the terms and conditions set forth in such Note; and

 

C.                
This Agreement, the Note, and all other certificates, agreements, documents and instruments delivered to any party under or in
connection with this Agreement, as the same may be amended from time to time, are collectively referred to herein as the “Transaction
Documents”.

 

In consideration of the mutual promises made herein
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree
as follows:

 

1.                 
Definitions. For the purposes of this Agreement, the following terms shall have the meanings set forth below:

 

“Affiliate” means, with respect
to any Person, any other Person which directly or indirectly through one or more intermediaries controls, is controlled by, or is under
common control with, such Person. A Person shall be deemed to control another Person if such Person possesses, directly or indirectly,
the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities,
by contract or otherwise. Without limiting the generality of the foregoing, a Person shall be deemed to control another Person if any
of the following conditions is met: (i) in the case of corporate entities, direct or indirect ownership of more than fifty percent (50%)
of the stock or shares having the right to vote for the election of directors, and (ii) in the case of non-corporate entities, direct
or indirect ownership of more than fifty percent (50%) of the equity interest with the power to direct the management and policies of
such non-corporate entities.

 

“Agreement” has the meaning
set forth in the preamble to this Agreement.

 

“Board” means the Company’s
Board of Directors.

 

“Business Day” means a day,
other than a Saturday, Sunday or United States federal holiday, on which banks in New York City are open for the general transaction of
business.

 

     

     

    

 

“Closing” has the meaning set
forth in Section 3.1.

 

“Closing Date” has the meaning
set forth in Section 3.1.

 

“Common Stock” has the meaning
set forth in Section 4.2 to this Agreement.

 

“Common Stock Equivalents” shall
mean any options, warrants or other securities or rights convertible into or exercisable or exchangeable for, whether directly or following
conversion into or exercise or exchange for other options, warrants or other securities or rights, Common Stock of the Company, or any
swap, hedge or similar agreement or arrangement that transfers in whole or in part, the economic risk of ownership of, or voting or other
rights of, Common Stock.

 

“Company” has the meaning set
forth in the preamble to this Agreement.

 

“Disposition” or “Dispose
of” shall mean any (i) pledge, sale, contract to sell, sale of any option or contract to purchase, purchase of any option or
contract to sell, grant of any option, right or warrant for the sale of, or other disposition of or transfer of any Common Stock or any
Common Stock Equivalents, including, without limitation, any “short sale” or similar arrangement, or (ii) swap or any other
agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the
Common Stock or any Common Stock Equivalents, whether any such swap or transaction is to be settled by delivery of securities, in cash
or otherwise.

 

“Domestication” shall mean the
process by which the Company was formally confirmed as the successor issuer to Summit Therapeutics plc pursuant to a United Kingdom court-approved
scheme of arrangement effective as of September 18, 2020.

 

“Enforceability Exceptions”
has the meaning set forth in Section 4.4(b).

 

“GAAP” means generally accepted accounting principles in
the United States set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified
Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or such other principles as may be approved
by a significant segment of the accounting profession in the United States, that are applicable to the circumstances as of the date of
determination, consistently applied.

 

“Governmental Authority” shall
mean any court, agency, authority, department, regulatory body or other instrumentality of any government or country or of any national,
federal, state, provincial, regional, county, city or other political subdivision of any such government or country or any supranational
organization of which any such country is a member.

 

“Group” means the Company and
its subsidiaries (and “Group Company” shall be construed accordingly).

 

“Investor” has the meaning set
forth in the preamble to this Agreement.

 

“Law” or “Laws”
shall mean all laws, statutes, rules, regulations, orders, judgments, injunctions and/or ordinances of any Governmental Authority.

 

    2 

     

    

 

“Material Adverse Effect” means
a material adverse effect on (i) the assets, liabilities, results of operations, financial condition or business of the Company and
its subsidiaries taken as a whole, (ii) the legality or enforceability of this Agreement or (iii) the ability of the Company
to perform its obligations under this Agreement.

 

“Nasdaq” means The Nasdaq Stock
Market LLC.

 

“Person” means an individual,
corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship,
unincorporated organization, Governmental Authority or any other form of entity not specifically listed herein.

 

“Press Release” has the meaning
set forth in Section 10.7.

 

“Purchase Price” has the meaning
set forth in Section 2.1.

 

“Sarbanes-Oxley Act” has the
meaning set forth in Section 4.10(g).

 

“SEC” has the meaning set forth
in the recitals to this Agreement.

 

“SEC Documents” has the meaning
set forth in Section 4.10(a).

 

“Short Sales” means all “short
sales” as defined in Rule 200 of Regulation SHO under the 1934 Act (but shall not be deemed to include the location and/or reservation
of borrowable Common Stock).

 

“Third Party” shall mean any
Person, including a Governmental Authority, other than the Investor, the Company or any Affiliate of the Investor or the Company or any
of their respective representatives.

 

“Trading Day” shall mean a day
on which trading in the Common Stock generally occurs on Nasdaq.

 

“Transaction Documents” has
the meaning set forth in the recitals to this Agreement.

 

“1933 Act” means the Securities
Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

“1934 Act” means the Securities
Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

“8-K Filing” has the meaning
set forth in Section 9.7.

 

2.                 
Purchase and Sale of the Note.

 

2.1.               
Subject to the terms and conditions of this Agreement, the Investor hereby agrees to purchase, and the Company agrees to issue
and sell to the Investor the Note. In consideration therefor, the Investor shall pay the Company the aggregate amount of fifty-five million
U.S. dollars ($55,000,000) (the “Purchase Price”).

 

    3 

     

    

 

3.                 
Closing.

 

3.1.               
The completion of the purchase and sale of the Note (the “Closing”) shall be on the date hereof (the “Closing
Date”). The Closing shall occur remotely on the Closing Date via exchange of documents and signatures or at such place as the
Company and the Investor may agree in writing.

 

3.2.               
On the Closing Date the Investor shall deliver or cause to be delivered to the Company the Purchase Price via wire transfer of
immediately available funds pursuant to the wire instructions delivered to the Investor by the Company in connection with the execution
of this Agreement. Upon the execution of this Agreement, the Company shall deliver or cause to be delivered the Note duly executed by
an authorized officer of the Company to the Investor.

 

4.                 
Representations and Warranties of the Company. The Company hereby represents and warrants to the Investor that, except as
otherwise described in this Agreement or the SEC Documents, which qualify these representations and warranties in their entirety:

 

4.1.               
Organization, Good Standing and Qualification. The Company has been duly organized and is validly existing and in good standing
under the laws of its jurisdiction of organization, is duly qualified to do business and is in good standing in each jurisdiction in which
its ownership or lease of property or the conduct of its businesses requires such qualification, and has all power and authority necessary
to own or hold its properties and to conduct the businesses in which it is engaged, except where the failure to be so qualified or in
good standing or have such power or authority would not, individually or in the aggregate, have a Material Adverse Effect.

 

4.2.               
Capitalization and Voting Rights.

 

(a)                  
As of March 31, 2021, the Company has 82,919,522 shares of the Company’s Common Stock, par value $0.01 (the “Common
Stock”) issued and outstanding. The Company has also (i) granted outstanding options under the Company’s equity incentive
plans over, in aggregate, 12,202,048 shares of Common Stock, (ii) granted restricted stock units under the Company’s directors’
remuneration policy over 0 shares of Common Stock and (iii) issued warrants for the purchase of up to 5,821,137 shares of Common Stock,
which are outstanding as of March 31, 2021. The issued share capital of the Company has been duly and validly issued and is fully paid
and non-assessable.

 

(b)                  
Except as described or referred to in Section 4.2(a) above, as of the date of this Agreement, there are no outstanding rights (including,
without limitation, pre-emptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any share
capital or other equity interest in the Company, or any contract, commitment, agreement, understanding or arrangement of any kind relating
to the issuance of any share capital of the Company, any such convertible or exchangeable securities or any such rights, warrants or options.

 

(c)                  
No Person has any right to cause the Company to effect the registration under the 1933 Act of any securities of the Company, which
have not been exercised prior to the date hereof.

 

(d)                  
The Company is not a party to or subject to any agreement or understanding relating to the voting of share capital of the Company
or the giving of written consents by a stockholder or director of the Company.

 

    4 

     

    

 

(e)                  
The execution and delivery of this Agreement, and the transactions contemplated hereby, will not result in the triggering of any
anti-dilution rights, or otherwise increase the number of shares of Common Stock issuable or decrease the exercise or conversion price,
under any warrant, option, convertible note or other instruments convertible or exchangeable for, any share capital or other equity interests
in the Company.

 

4.3.               
Subsidiaries. All the outstanding share capital or other equity interests of each subsidiary owned, directly or indirectly,
by the Company have been duly authorized and validly issued, are fully paid and are owned directly or indirectly by the Company, free
and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party.

 

4.4.               
Authorization.

 

(a)                  
The Company has the requisite corporate power and authority to execute and deliver this Agreement and to perform its obligations
hereunder; and all action required to be taken (including the approval of the Board and of the independent Special Committee of the Board
formed in connection with the Company’s consideration of the transactions undertaken pursuant to the Transaction Documents) for
the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated
hereby and thereby has been duly and validly taken.

 

(b)                  
This Agreement and the other Transaction Documents have been duly executed and delivered by the Company, and this Agreement and
the other Transaction Documents (as and when executed and delivered in accordance with the terms and conditions of the Agreement) constitute
valid and legally binding obligations of the Company, enforceable against the Company in accordance with their terms, except as enforceability
may be limited by applicable bankruptcy, insolvency or similar laws affecting creditors’ rights generally or by equitable principles
relating to enforceability (collectively, the “Enforceability Exceptions”).

 

(c)                  
No stop order or suspension of trading of the Company’s equity securities has been imposed by the SEC, Nasdaq, or any other
Governmental Authority and remains in effect.

 

4.5.               
No Defaults. The Company is not (i) in violation of its certificate of incorporation or bylaws; (ii) in default, and no
event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of
any term, covenant or condition contained in any indenture, mortgage or loan agreement to which the Company is a party or by which the
Company is bound or to which any of the property or assets of the Company is subject; (iii) in default, and no event has occurred that,
with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition
contained in any deed of trust or other agreement or instrument to which the Company is a party or by which the Company is bound or to
which any of the property or assets of the Company is subject (except for any agreements referred to in clause (ii) above); or (iv) in
violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority
having jurisdiction over the Company or any of its subsidiaries, except, in the case of clauses (iii) and (iv) above, for any such default
or violation that would not, individually or in the aggregate, have a Material Adverse Effect.

 

    5 

     

    

 

4.6.               
No Conflicts. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated
hereby will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under,
or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to, any
indenture, mortgage or loan agreement to which the Company is a party or by which the Company is bound or to which any of the property
or assets of the Company is subject, (ii) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute
a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company
pursuant to, any deed of trust or other agreement or instrument to which the Company is a party or by which the Company is bound or to
which any of the property or assets of the Company is subject (except for any agreements referred to in clause (i) above), (iii) result
in any violation of the provisions of the Company’s certificate of incorporation or bylaws or (iv) result in the violation of any
law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority having jurisdiction
over the Company or any of its subsidiaries, except, in the case of clauses (ii) and (iv) above, for any such conflict, breach, violation
or default that would not, individually or in the aggregate, have a Material Adverse Effect.

 

4.7.               
No Governmental Authority or Consents. No consent, approval, authorization, order, license, registration or qualification
of or with any court or arbitrator, governmental or regulatory authority is required for the execution, delivery and performance by the
Company of this Agreement, or the issuance and sale of the Note, except such filings as may be required to be made with the SEC or under
any state securities laws, foreign securities laws, blue sky laws, or the rules and regulations of Nasdaq, which filings shall be made
in a timely manner in accordance with all applicable Laws.

 

4.8.               
Litigation. There are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to which
the Company or any of its subsidiaries is a party or to which any property of the Company or any of its subsidiaries is subject that,
individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect; and no such investigations, actions,
suits or proceedings are threatened or, to the knowledge of the Company, contemplated by any governmental or regulatory authority or threatened
by others.

 

4.9.               
Licenses and Other Rights; Compliance with Laws. The Company and its subsidiaries possess or are in the process of obtaining
all licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate
federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective
properties or the conduct of their respective businesses as described in the SEC Documents, except where the failure to possess or make
the same would not, individually or in the aggregate, have a Material Adverse Effect; and neither the Company nor any of its subsidiaries
has received notice of any revocation or modification of any such license, certificate, permit or authorization or has any reason to believe
that any such license, certificate, permit or authorization will not be renewed in the ordinary course. For the avoidance of doubt and
notwithstanding the foregoing, neither the Company nor any subsidiary has applied for or holds any product licenses or marketing authorizations
for any pharmaceutical products.

 

    6 

     

    

 

4.10.           
SEC Documents; Financial Statements; Nasdaq Stock Market.

 

(a)                  
Since January 1, 2020, the Company has timely filed all required reports, schedules, forms, statements and other documents (including
exhibits and all other information incorporated therein), and any required amendments to any of the foregoing, with the SEC (the “SEC
Documents”). As of their respective filing dates, each of the Company SEC Documents complied in all material respects with the
requirements of the 1933 Act and the 1934 Act, and the rules and regulations of the SEC promulgated thereunder applicable to such Company
SEC Documents, and no Company SEC Documents when filed, declared effective or mailed, as applicable, contained any untrue statement of
a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading.

 

(b)                  
Since January 1, 2020, the Company has filed all notices and documents required to be filed by it under the Nasdaq listing rules.
Each such notice or document was filed within the applicable timeframe prescribed by the Nasdaq listing rules. As of their respective
dates, each such notice or document complied in all material respects with the applicable requirements of the Nasdaq listing rules.

 

(c)                  
As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC or its
staff.

 

(d)                  
The financial statements of the Company for the fiscal year ended December 31, 2020 (included in the Company’s Annual Report
on Form 10-K filed with the SEC on March 31, 2021) present fairly the financial position of the Company and its consolidated subsidiaries
as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial
statements have been prepared in conformity with GAAP, applied on a consistent basis throughout the periods covered thereby, except as
otherwise disclosed therein and, in the case of unaudited, interim financial statements, subject to normal year-end audit adjustments
and the exclusion of certain footnotes, and any supporting schedules included in the SEC Documents present fairly the information required
to be stated therein.

 

(e)                  
As of the date hereof, the Common Stock of the Company is admitted to trading on Nasdaq. The Company has taken no action designed
to, or which is likely to have the effect of, terminating the registration of the Common Stock under the 1934 Act or delisting the Common
Stock from Nasdaq. The Company has not received any notification that the SEC or Nasdaq, as applicable, is contemplating terminating such
registration or listing.

 

(f)                   
The Company and its subsidiaries have established systems of “internal control over financial reporting” (as defined
in Rule 13a-15(f) of the 1934 Act) that have been designed by, or under the supervision of, their respective principal executive and principal
financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting
controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or
specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with
GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific
authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate
action is taken with respect to any differences.

 

    7 

     

    

 

(g)                  
There is and has been no material failure on the part of the Company or any of the Company’s directors or officers, in their
capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated
in connection therewith (the “Sarbanes-Oxley Act”), including Section 402 related to loans and Sections 302 and 906
related to certifications.

 

4.11.           
Interim Financials. The published interim results of the Company and its consolidated subsidiaries for the three months
ended September 30, 2020 and the three months and six months ended June 30, 2020 have been prepared with all due care and attention (having
regard to the fact that the results were made publicly available) and on accounting bases and assumptions consistent with those adopted
in the preparation of the audited financial statements of the Company and its consolidated subsidiaries for the fiscal year period ended
December 31, 2020 and the interim results of the Company and its consolidated subsidiaries as published in the Company’s Quarterly
Report on Form 10-Q filed with the SEC on November 16, 2020 and, with respect to the periods ended June 30, 2020, the Company’s
Current Report on Form 8-K filed with the SEC on September 29, 2020, except as otherwise disclosed therein.

 

4.12.           
Absence of Certain Changes. Since the financial statements of the Company for the fiscal year ended December 31, 2020 (included
in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2021) were prepared: the businesses of the Company and
its consolidated subsidiaries have been carried on in the ordinary and usual course; there has been no significant adverse change in the
financial or trading position of the Company taken as a whole or, to the best of the Company’s knowledge, information and belief,
prospects of the Company; the Company has not acquired or disposed of or agreed to acquire or dispose of any of its assets or businesses
other than in the ordinary course of trading; the Company has not entered into any contract or commitment of an unusual, long-term and/or
onerous nature or assumed any material liabilities (including contingent liabilities) (other than as contemplated by this Agreement);
excluding the distribution of rights announced by the Company on March 26, 2021 and disclosed in the SEC Documents, the Company has not
paid or made any payment or transfer to shareholders of any dividend, bonus, loan or distribution other than to the directors of the Company
in their capacity as such directors in a manner consistent with the compensation of such directors as disclosed in the SEC Documents;
and the Company has complied in all material respects with all the listing requirements of Nasdaq applicable to the Company (including
the disclosure and notification requirements) and any requests for disclosure made by Nasdaq.

 

4.13.           
Tax. All returns of each member of the Group for taxation purposes have been made for all periods up to and including December
31, 2019, and all such returns are correct, and are not the subject of any dispute with or claim by HM Revenue & Customs or other
relevant taxation authority (other than routine audits) which would be material to the Company are not likely to result in any such dispute
or claim.

 

4.14.           
Environmental. So far as the Company is aware, none of the Company nor any member of the Group has any material obligation
or liability with respect to pollution, hazardous substances or environmental matters and there are no circumstances which the Company
considers are likely to give rise to the same.

 

4.15.           
Insurance. The Company and each member of the Group maintain such insurance coverage against fire and other risks upon all
their assets and such public and employers’ liability as the directors of each such company consider appropriate, taking into account
the nature and scale of their activities, the provisions of agreements binding upon it, such insurance is now in force. The Company is
not aware of any fact or matter which would lead to any such insurance being vitiated or repudiated, there is no material claim pending
or outstanding and all premiums in respect of such insurances are duly paid.

 

    8 

     

    

 

4.16.           
Intellectual Property.

 

(a)                  
Each member of the Group has (i) acted reasonably in seeking professional advice with regard to filing patent applications in respect
of material new inventions; (ii) adopted commercially reasonable and prudent practices with regard to the protection, prosecution and
maintenance of its portfolio of patents, patent applications and trademarks and other material intellectual property and the payment of
renewal fees in respect thereof; (ii) adopted commercially reasonable and prudent practices to capture intellectual property rights in
respect of material new inventions; and (iv) used commercially reasonable practices to protect the confidentiality of all material non-patented
know how. None of the intellectual property relating to the business of any member of the Group is the subject of any claim, opposition,
assertion, infringement, attack, right, action or other restriction or arrangement of whatsoever nature which does or may impinge upon
the validity, enforceability or ownership of the same or the utilization thereof by any member of the Group to an extent which is material
in the context of the Group. So far as the Company is aware, and not having obtained freedom to operate opinions in respect of all of
its intellectual property rights, none of the activities of any member of the Group infringes in any material respect any right of any
other person relating to intellectual property or gives rise to a material liability for any royalty or similar payment.

 

(b)                  
The intellectual property used or enjoyed by each member of the Group in connection with its business at the date of this Agreement,
and which is material to such business, is either legally and beneficially owned by that member of the Group, or licensed to, or used
under the authority of the owner by, that member of the Group and are not subject to any mortgage, charge, lien or other security interest
in favor of any third party save as registered with the United States Patent and Trademark Office or the Registrar of Companies in the
United Kingdom.

 

4.17.           
Offering. Subject to the accuracy of the Investor’s representations set forth in Section 5, the offer, sale and issuance
of the Note to be issued in conformity with the terms of this Agreement, constitute transactions which are exempt from the registration
requirements of the 1933 Act and from all applicable state registration or qualification requirements.

 

4.18.           
No Integration. The Company has not, directly or through any agent, sold, offered for sale, solicited offers to buy or otherwise
negotiated in respect of, any security (as defined in the 1933 Act), that is or will be integrated with the sale of the Note thereunder
in a manner that would require registration of such securities under the 1933 Act.

 

4.19.           
Brokers’ or Finders’ Fees. Neither the Company nor any of its subsidiaries is a party to any contract, agreement
or understanding with any person that would give rise to a valid claim against the Company or any of its subsidiaries for a brokerage
commission, finder’s fee or like payment in connection with the transactions contemplated by this Agreement.

 

    9 

     

    

 

4.20.           
No General Solicitation. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the
securities to be issued pursuant to this Agreement by any form of general solicitation or general advertising. The Company has offered
the Note for sale only to the Investor.

 

4.21.           
Foreign Corrupt Practices. None of the Company, any of its subsidiaries, nor to the knowledge of the Company, any agent
or other person acting on behalf of the Company or any of its subsidiaries, has: (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any of its subsidiaries (or made by any person acting on
its or their behalf of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision
of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable non-U.S. anti-bribery Law.

 

4.22.           
Regulation M Compliance. The Company has not taken, directly or indirectly, any action designed to or that would reasonably
be expected to cause or result in stabilization or manipulation of any of its securities to facilitate the sale or resale of the Note.

 

4.23.       
Investment Company. The Company is not required to be registered as, and is not an Affiliate of, and immediately following
the Closing will not be required to register as, an “investment company” within the meaning of the Investment Company Act
of 1940, as amended.

 

4.24.           
Disclosures. The SEC Documents, when considered together, do not contain any untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements contained therein, in light of the circumstances under which they were
made, not misleading, other than with respect to the transactions contemplated by this Agreement and except as will be disclosed pursuant
to Section 10.7.

 

5.                 
Representations and Warranties of the Investor. The Investor hereby represents and warrants to the Company that:

 

5.1.               
Authority. The Investor is an individual with power and authority to enter into and consummate the transactions contemplated
by this Agreement and to carry out its obligations thereunder, and to invest in the Note pursuant to this Agreement.

 

5.2.               
Authorization. This Agreement has been duly executed and delivered by the Investor, and this Agreement constitutes a valid
and legally binding obligation of the Investor, enforceable against the Investor in accordance with its terms, except as enforceability
may be limited by the Enforceability Exceptions.

 

5.3.               
No Conflicts. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated
by this Agreement and the other Transaction Documents will not (i) conflict with or result in a breach or violation of any of the terms
or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property
or assets of the Investor pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which
the Investor is a party or by which the Investor is bound or to which any of the property or assets of the Investor is subject, or (ii)
result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or
regulatory authority having jurisdiction over the Investor except, in the case of clauses (i) and (ii) above, for any such conflict, breach,
violation or default that would not, individually or in the aggregate, have a material adverse effect on the Investor’s ability
to perform its obligations or consummate the transactions contemplated by this Agreement.

 

    10 

     

    

 

5.4.               
Purchase Entirely for Own Account. The Note to be received by the Investor hereunder will be acquired for the Investor’s
own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act,
and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of
the 1933 Act, without prejudice, however, to such Investor’s right at all times to sell or otherwise dispose of all or any part
of the Note in compliance with the terms of the Note and any applicable federal and state securities laws. The Investor is not
a broker-dealer registered with the SEC under the 1934 Act or an entity engaged in a business that would require it to be so registered.

 

5.5.               
Investment Experience. The Investor acknowledges that it can bear the economic risk and complete loss of its investment
in the Note and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks
of the investment contemplated hereby.

 

5.6.               
Disclosure of Information. The Investor has had an opportunity to receive, review and understand all information related
to the Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the
terms and conditions of the offering of the Note, and has conducted and completed its own independent due diligence. The Investor acknowledges
that copies of the SEC Documents are available on the SEC’s EDGAR system. Based on such information as the Investor has deemed appropriate
and the representations and warranties of the Company contained in Section 4 of this Agreement, and without reliance upon any other party,
it has independently made its own analysis and decision to enter into this Agreement. The Investor has sought such accounting, legal and
tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of the Note.

 

5.7.               
Restricted Securities. The Investor understands that the Note will be characterized as “restricted securities”
under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering
and that under such laws and applicable regulations such securities may be resold without registration under the 1933 Act only in certain
limited circumstances. The Investor acknowledges that the Company has no obligation to register or qualify the Note for resale. The Investor
further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements
including, but not limited to, the time and manner of sale, the holding period for the Note, and on requirements relating to the Company
which are outside of the Investor’s control, and which the Company is under no obligation and may not be able to satisfy.

 

5.8.               
Legends. It is understood that, the Note bears a restrictive legend in accordance with the requirements of the Securities
Act of 1933 limiting the Investors right to dispose of the Note.

 

    11 

     

    

 

5.9.               
Accredited Investor. The Investor is an “accredited investor” within the meaning of Rule 501 under the 1933
Act and has executed and delivered to the Company a questionnaire in substantially the form attached hereto as Exhibit C (the “Investor
Questionnaire”), which such Investor represents and warrants is true, correct and complete. The Investor is a sophisticated
investor with sufficient knowledge and experience in investing in private equity transactions to properly evaluate the risks and merits
of its purchase of the Note. Such Investor has determined based on its own independent review and such professional advice as it deems
appropriate that its purchase of the Note and participation in the transactions contemplated by this Agreement (i) are fully consistent
with its financial needs, objectives and condition, (ii) comply and are fully consistent with all investment policies, guidelines and
other restrictions applicable to such Investor, (iii) have been duly authorized and approved by all necessary action, (iv) do not and
will not violate or constitute a default under any law, rule, regulation, agreement or other obligation by which such Investor is bound
and (v) are a fit, proper and suitable investment for such Investor, notwithstanding the substantial risks inherent in investing in or
holding the Note.

 

5.10.           
No General Solicitation. The Investor did not learn of the investment in the Note as a result of any general solicitation
or general advertising.

 

5.11.           
Brokers and Finders. No Person will have, as a result of the transactions contemplated by this Agreement, any valid right,
interest or claim against or upon the Company or the Investor for any commission, fee or other compensation pursuant to any agreement,
arrangement or understanding entered into by or on behalf of the Investor.

 

5.12.           
Short Sales and Confidentiality Prior to the Date Hereof.  Other than consummating the transactions contemplated hereunder,
the Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with the Investor, directly or indirectly
executed any purchases or sales, including Short Sales, of the securities of the Company or directly or indirectly engaged in any
action designed to, or which might be reasonably expected to, cause or result in any manipulation of the price of the securities of the
Company during the period commencing as of the time that such Investor was first contacted by the Company or any other Person regarding
the transactions contemplated hereby and ending immediately prior to the date hereof.  The Investor has maintained the confidentiality
of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to the identification of the availability of, or securing of, available securities to borrow in order to effect Short Sales
or similar transactions in the future.

 

5.13.           
No Government Recommendation or Approval. The Investor understands that no United States federal or state agency, or similar
agency of any other country, has reviewed, approved, passed upon, or made any recommendation or endorsement of the Company or the purchase
of the Note.

 

5.14.           
No Rule 506 Disqualifying Activities. The Investor has not taken any of the actions set forth in, and is not subject to,
the disqualification provisions of Rule 506(d)(1) of the 1933 Act.

 

    12 

     

    

 

6.                 
Covenants and Agreements of the Company and the Investor.

 

6.1.               
No Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment that would
conflict or interfere in any material respect with the Company’s obligations to the Investor under this Agreement.

 

6.2.               
Removal of Legends.

 

(a)                  
In connection with any sale, assignment, transfer or other disposition of the Note by the Investor pursuant to Rule 144 or
pursuant to any other exemption under the 1933 Act such that the purchaser acquires freely tradable securities and upon compliance by
the Investor with the requirements of this Agreement, if requested by the Investor, the Company shall use commercially reasonable efforts
to remove any restrictive legends that appear on the Note and to issue a new, unlegended Note without restrictive legends, provided that
the Company has received from the Investor customary representations and other documentation reasonably acceptable to the Company in connection
therewith and, if necessary, otherwise sufficient to support any required legal opinion with respect thereto.

 

(b)                  
Subject to receipt from the Investor by the Company of customary representations and other documentation reasonably acceptable
to the Company in connection therewith and, if necessary, otherwise sufficient to support any required legal opinion with respect thereto,
upon the earliest of such time as the Note (i) has been sold or transferred pursuant to an effective registration statement, (ii) has
been sold pursuant to Rule 144, or (iii) is eligible for resale under Rule 144(b)(1) or any successor provision (such earliest date,
the “Effective Date”), the Company shall issue a new, unlegended Note. The Company agrees that following the Effective
Date or at such time as such legend is no longer required under this Section 6.2, it will, following the delivery by the Investor to the
Company of the Note issued with a restrictive legend, use commercially reasonable efforts to deliver or cause to be delivered to such
Investor a new, unlegended Note that is free from all restrictive and other legends. The Company may not make any notation on its records
that enlarge the restrictions on transfer set forth in this Section 6.2.

 

(c)                  
Subject to the restrictions on dispositions pursuant to Section 7.1 of this Agreement, the Investor agrees with the Company that
the Investor will sell the Note only in compliance with an exemption from the registration requirements of the 1933 Act.

 

6.3.               
Subsequent Equity Sales. The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate
of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2
of the 1933 Act) that will be integrated with the offer or sale of the Note in a manner that would require the registration under the
1933 Act of the sale of the Note to the Investor, or that will be integrated with the offer or sale of the Note for purposes of the rules
and regulations of any trading market such that it would require shareholder approval prior to the closing of such other transaction unless
shareholder approval is obtained before the closing of such subsequent transaction.

 

6.4.               
Short Sales and Confidentiality After the Date Hereof. The Investor covenants that neither it nor any Affiliates acting
on its behalf or pursuant to any understanding with it will execute any Short Sales during the period from the date hereof until such
time as the transactions contemplated by this Agreement are first publicly announced. The Investor covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company, the Investor will maintain the confidentiality of all
disclosures made to it in connection with this transaction (including the existence and terms of this transaction). The Investor understands
and acknowledges that the SEC currently takes the position that coverage of Short Sales of securities “against the box” prior
to effectiveness of a resale registration statement with securities included in such registration statement would be a violation of Section
5 of the 1933 Act, as set forth in Item 239.10 of the Securities Act Rules Compliance and Disclosure Interpretations compiled by the Office
of Chief Counsel, Division of Corporation Finance.

 

    13 

     

    

 

7.                 
Acknowledgements.

 

7.1.               
Insider Trading. In addition to the restrictions in this Agreement on the Disposition of Common Stock and Common Stock Equivalents
of the Company, the Investor hereby acknowledges that it is aware that United States securities Laws prohibit any person who has material,
non-public information about a company obtained directly or indirectly from that company from purchasing or selling securities of such
company or from communicating such information to any other person, including under circumstances in which it is reasonably foreseeable
that such person is likely to purchase or sell such securities.

 

8.                 
Survival. The representations, warranties, covenants and agreements contained in this Agreement shall survive the Closing
of the transactions contemplated by this Agreement for the applicable statute of limitations.

 

9.                 
Miscellaneous.

 

9.1.               
Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent of the Company
or the Investor, as applicable. The provisions of this Agreement shall inure to the benefit of and be binding upon the respective permitted
successors and assigns of the parties.

 

9.2.               
Counterparts; E-mail. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. This Agreement may also be executed via electronic mail, which
shall be deemed an original.

 

9.3.               
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement.

 

9.4.               
Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and
shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given
upon such delivery, (ii) if given by electronic mail, then such notice shall be deemed given upon receipt of confirmation of complete
transmittal, and (iii) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one
Business Day after delivery to such carrier. All notices shall be addressed to the party to be notified at the address as follows, or
at such other address as such party may designate by ten days’ advance written notice to the other party:

 

    14 

     

    

 

If to the Company:

 

Summit Therapeutics Inc.

One Broadway, 14th Floor

Cambridge, MA 02142

Attention: Chief Financial Officer

Email: Mike.Donaldson@summitplc.com

 

With a copy to:

 

Olshan Frome Wolosky LLP

1325 Avenue of the Americas

New York, New York 10019

Attention: Adam W. Finerman

Email: AFinerman@olshanlaw.com

 

If to the Investor:

 

to the address set forth on Exhibit
A hereto.

 

9.5.               
Expenses. The parties hereto shall pay their own costs and expenses in connection herewith regardless of whether the transactions
contemplated hereby are consummated; it being understood that each of the Company and the Investor has relied on the advice of its own
respective counsel and/or other professional advisers.

 

9.6.               
Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be
waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the
Company and the Investor.

 

9.7.               
Publicity. Except as set forth below, no public release or announcement concerning the transactions contemplated hereby
shall be issued by the Investor without the prior consent of the Company (which consent shall not be unreasonably withheld), except as
such release or announcement may be required by law or the applicable rules or regulations of any securities exchange or securities market,
in which case the Investor shall allow the Company, to the extent reasonably practicable in the circumstances, reasonable time to comment
on such release or announcement in advance of such issuance. The Company shall not include the name of the Investor in any press release
or public announcement (which, for the avoidance of doubt, shall not include any filing with the SEC) without the prior written consent
of the Investor, except as otherwise required by law or the applicable rules or regulations of any securities exchange or securities market,
in which case the Company shall allow the Investor, to the extent reasonably practicable in the circumstances, reasonable time to comment
on such release or announcement in advance of such issuance. Promptly following the date this Agreement is executed, the Company shall
issue a press release disclosing all material terms of transactions contemplated by this Agreement (the “Press Release”)
and make an announcement thereof (including the name of the Investor) to a Regulatory Investment Service. No later than 5:30 p.m. (New
York City time) on the fourth Business Day following the date this Agreement is executed, the Company will file a Report on Form 8-K (the
“8-K Filing”) attaching the press release described in the foregoing sentence as well as a copy of this Agreement.
In addition, the Company will make such other filings and notices in the manner and time required by the SEC or Nasdaq. The parties acknowledge
that from and after the issuance of the Press Release, the Investor shall not be in possession of any material, nonpublic information
received from the Company or any of its respective officers, directors, employees or agents, with respect to the transactions contemplated
hereby that is not disclosed in the Press Release.

 

    15 

     

    

 

9.8.               
Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such
jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof
but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such
prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.
To the extent permitted by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited
or unenforceable in any respect.

 

9.9.               
Entire Agreement. This Agreement, including the signature pages and Exhibits hereto, constitutes the entire agreement among
the parties hereof with respect to the subject matter hereof and thereof and supersedes all prior agreements and understandings, both
oral and written, between the parties with respect to the subject matter hereof and thereof.

 

9.10.           
Further Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other
actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements
herein contained.

 

9.11.           
Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance
with, the internal laws of the State of New York without regard to the choice of law principles thereof. Each of the parties hereto irrevocably
submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District
Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of
this Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may
be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement.
Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the
laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding
brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought
in an inconvenient forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO
THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

[remainder of page intentionally left blank]

 

    16 

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written.

 

	COMPANY:	
    Summit Therapeutics INC.

     

	 	By: 	/s/ Michael Donaldson
	 	 	Name: Michael Donaldson
	 	 	
    Title: Chief Financial Officer

     

	INVESTOR:	 	 
	 	By: 	/s/ Robert W. Duggan
	 	 	
    Name: Robert W. Duggan

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]